4.5 Letter

Lichen Ruber Planus occurring after SARS-CoV-2 vaccination

Related references

Note: Only part of the references are listed.
Letter Dermatology

High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2

Xiaotong Xue et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Letter Dermatology

Annular lichen planus associated with coronavirus SARS-CoV-2 disease (COVID-19)

Borja Diaz-Guimaraens et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2021)

Review Immunology

The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo

Azin Aghamajidi et al.

Summary: T cell-mediated autoimmune skin diseases arise from aberrant immune response to skin cells, with immunomodulating agents proving successful in their management thanks to improved understanding of pathophysiology. This study discusses immunopathogenic mechanisms and the role of T lymphocytes in these diseases, offering new insights into targeted therapeutic pathways and biological therapies.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2021)

Letter Dermatology

Lichen planus arising after COVID-19 vaccination

I. Hiltun et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Letter Dermatology

Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine

P. K. Krajewski et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Article Dermatology

The inflammation in cutaneous lichen planus is dominated by IFN-Υ and IL-21-A basis for therapeutic JAK1 inhibition

Katharina Pietschke et al.

Summary: Cutaneous lichen planus (CLP) and psoriasis (PSO) are common chronic inflammatory skin diseases with distinct immune signatures, characterized by different cytokine expressions and cellular infiltrates in lesional skin. This study provides insights into the dominant immunological factors in CLP, suggesting potential therapeutic targets such as JAK inhibitors.

EXPERIMENTAL DERMATOLOGY (2021)